What factors drove the changes in Diamedica's revenue and profit?

What does Diamedica do and what are its main business segments?

What is the revenue and EPS growth rate for Diamedica year over year?

What is the market's earnings forecast for Diamedica next quarter?

What is Diamedica's latest dividend and current dividend yield?

What were the key takeaways from Diamedica's earnings call?

What were the key takeaways from Diamedica’s earnings call?

What is Diamedica's gross profit margin?

- **Preeclampsia progress**: DM199 shows dose-dependent BP drops (systolic/diastolic) and placental perfusion improvements, positioning for U.S. trial.
- **Stroke challenges**: Enrollment halved due to AI referrals; 35+ sites activated, seeking global expansion.
- **Financial stability**: $55.3M cash, net loss up 37% YoY driven by clinical costs.
- **Key milestones**: Cohort 10 expansion, FDA pre-IND update, and ReMEDy2 interim analysis in H2 2026.


**【CEO Summary Section】**
- Presented progress in preeclampsia and stroke programs, highlighting DM199's mechanism via bradykinin pathway activation.
- Preeclampsia interim results: Dose-dependent blood pressure reductions (systolic/diastolic) and uterine artery pulsatility index improvement, supporting placental perfusion claims.
- Stroke program updates: Enrollment challenges due to AI-driven referral shifts, revised U.S. trial plans for early onset preeclampsia, and $55.3M cash as of Q3 2025.
- Q&A emphasized KOL engagement, FDA pre-IND meeting progress, and Cohort 10's 12-patient expansion for U.S. trial preparation.

**【CFO Financial Commentary】**
- Cash position: $55.3M (vs. $30M prior quarter), sufficient for operations into 2027.
- R&D expenses: $6.4M/Q3, up 28% YoY, driven by ReMEDy2 expansion and preeclampsia trial costs.
- G&A: $2.6M/Q3, +37% YoY due to team expansion and IR/patent costs.
- Net loss: $8.6M/Q3, +37% YoY from clinical and manufacturing expenses.

**【Q&A Key Highlights】**
- Preeclampsia: KOLs praise placental barrier safety and blood pressure consistency; Cohort 10 IV-only dosing for U.S. trial.
- Stroke: Enrollment rates halved due to tele-neurology; 35+ sites activated, seeking OUS approvals.
- Interim analysis: Modified Rankin Scale targeting 15% improvement in non-thrombectomy patients.


DMAC

DMAC fundamentals

You can ask Aime